MiMedx Group (MDXG) Downgraded to Sell at BidaskClub
BidaskClub downgraded shares of MiMedx Group (NASDAQ:MDXG) from a hold rating to a sell rating in a report issued on Wednesday morning.
A number of other equities analysts also recently issued reports on the stock. Zacks Investment Research downgraded shares of MiMedx Group from a hold rating to a sell rating in a report on Friday, December 8th. Piper Jaffray Companies reiterated a buy rating and issued a $18.00 price target on shares of MiMedx Group in a report on Friday, December 1st. Needham & Company LLC reiterated a buy rating and issued a $21.00 price target on shares of MiMedx Group in a report on Tuesday, November 14th. Lake Street Capital set a $18.00 price target on shares of MiMedx Group and gave the company a buy rating in a report on Thursday, December 14th. Finally, Craig Hallum reiterated a buy rating on shares of MiMedx Group in a report on Tuesday, February 27th. Four research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have given a buy rating to the stock. The company presently has a consensus rating of Hold and a consensus target price of $14.75.
MiMedx Group (NASDAQ MDXG) opened at $7.59 on Wednesday. The stock has a market cap of $899.65, a PE ratio of 25.30, a PEG ratio of 0.92 and a beta of 1.65. MiMedx Group has a twelve month low of $6.05 and a twelve month high of $18.25.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Argent Capital Management LLC grew its stake in MiMedx Group by 37.2% in the 3rd quarter. Argent Capital Management LLC now owns 254,810 shares of the medical equipment provider’s stock valued at $3,027,000 after acquiring an additional 69,085 shares during the last quarter. Wells Fargo & Company MN grew its stake in MiMedx Group by 5.6% in the 3rd quarter. Wells Fargo & Company MN now owns 715,280 shares of the medical equipment provider’s stock valued at $8,498,000 after acquiring an additional 37,743 shares during the last quarter. Paradigm Capital Management Inc. NY grew its stake in MiMedx Group by 2.4% in the 4th quarter. Paradigm Capital Management Inc. NY now owns 419,100 shares of the medical equipment provider’s stock valued at $5,285,000 after acquiring an additional 10,000 shares during the last quarter. NorthCoast Asset Management LLC acquired a new stake in MiMedx Group in the 4th quarter valued at about $623,000. Finally, Crossmark Global Holdings Inc. acquired a new stake in MiMedx Group in the 3rd quarter valued at about $594,000. 71.15% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This news story was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/mimedx-group-mdxg-downgraded-to-sell-at-bidaskclub/1906108.html.
MiMedx Group Company Profile
MiMedx Group, Inc is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company’s Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories.
Receive News & Ratings for MiMedx Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiMedx Group and related companies with MarketBeat.com's FREE daily email newsletter.